Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| pericyte | 40 studies | 46% ± 17% | |
| endothelial cell | 39 studies | 39% ± 18% | |
| smooth muscle cell | 36 studies | 49% ± 19% | |
| fibroblast | 36 studies | 36% ± 17% | |
| endothelial cell of lymphatic vessel | 22 studies | 35% ± 15% | |
| myofibroblast cell | 13 studies | 42% ± 20% | |
| type I pneumocyte | 12 studies | 46% ± 22% | |
| mesothelial cell | 12 studies | 47% ± 24% | |
| type II pneumocyte | 11 studies | 53% ± 23% | |
| epithelial cell | 11 studies | 40% ± 15% | |
| basal cell | 11 studies | 34% ± 16% | |
| endothelial cell of vascular tree | 11 studies | 28% ± 12% | |
| connective tissue cell | 10 studies | 35% ± 11% | |
| ciliated cell | 10 studies | 30% ± 10% | |
| capillary endothelial cell | 10 studies | 28% ± 10% | |
| adipocyte | 10 studies | 69% ± 18% | |
| endothelial cell of artery | 9 studies | 24% ± 5% | |
| vein endothelial cell | 9 studies | 29% ± 5% | |
| club cell | 8 studies | 56% ± 18% | |
| astrocyte | 8 studies | 37% ± 17% | |
| retinal ganglion cell | 7 studies | 80% ± 19% | |
| epithelial cell of proximal tubule | 6 studies | 40% ± 16% | |
| cardiac muscle cell | 6 studies | 68% ± 21% | |
| secretory cell | 5 studies | 33% ± 13% | |
| cholangiocyte | 4 studies | 71% ± 18% | |
| hepatocyte | 4 studies | 66% ± 20% | |
| podocyte | 4 studies | 59% ± 31% | |
| abnormal cell | 4 studies | 35% ± 15% | |
| respiratory goblet cell | 4 studies | 51% ± 17% | |
| myoepithelial cell | 4 studies | 58% ± 25% | |
| kidney loop of Henle epithelial cell | 4 studies | 41% ± 17% | |
| renal alpha-intercalated cell | 4 studies | 48% ± 20% | |
| renal principal cell | 4 studies | 69% ± 25% | |
| squamous epithelial cell | 3 studies | 39% ± 20% | |
| hepatic stellate cell | 3 studies | 71% ± 11% | |
| kidney distal convoluted tubule epithelial cell | 3 studies | 37% ± 18% | |
| interstitial cell of Cajal | 3 studies | 71% ± 12% | |
| lymphocyte | 3 studies | 24% ± 8% | |
| muscle cell | 3 studies | 72% ± 18% | |
| hematopoietic stem cell | 3 studies | 27% ± 9% | |
| adventitial cell | 3 studies | 31% ± 13% | |
| mucus secreting cell | 3 studies | 32% ± 11% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| lung | 10 studies | 31% ± 13% | |
| heart | 6 studies | 41% ± 15% | |
| intestine | 5 studies | 21% ± 6% | |
| kidney | 5 studies | 42% ± 21% | |
| liver | 3 studies | 45% ± 13% | |
| uterus | 3 studies | 28% ± 6% | |
| breast | 3 studies | 29% ± 13% | |
| brain | 3 studies | 23% ± 8% | |
| placenta | 3 studies | 25% ± 4% | |
| adipose | 3 studies | 55% ± 26% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 100% | 16798.63 | 89 / 89 | 100% | 67.15 | 900 / 901 |
| thymus | 100% | 15742.17 | 650 / 653 | 97% | 46.51 | 586 / 605 |
| prostate | 99% | 20880.80 | 242 / 245 | 96% | 24.66 | 480 / 502 |
| breast | 100% | 17516.26 | 459 / 459 | 93% | 24.78 | 1041 / 1118 |
| bladder | 100% | 33872.76 | 21 / 21 | 91% | 20.99 | 458 / 504 |
| lung | 99% | 11035.35 | 573 / 578 | 86% | 21.26 | 999 / 1155 |
| esophagus | 92% | 33295.35 | 1332 / 1445 | 89% | 19.19 | 163 / 183 |
| intestine | 92% | 24704.97 | 884 / 966 | 88% | 15.24 | 465 / 527 |
| ovary | 99% | 19059.26 | 179 / 180 | 75% | 12.99 | 324 / 430 |
| uterus | 99% | 23300.72 | 168 / 170 | 76% | 20.87 | 347 / 459 |
| stomach | 79% | 14272.74 | 284 / 359 | 90% | 20.31 | 257 / 286 |
| adrenal gland | 97% | 7506.07 | 251 / 258 | 63% | 10.20 | 144 / 230 |
| liver | 69% | 4670.90 | 156 / 226 | 88% | 17.33 | 357 / 406 |
| skin | 44% | 2770.04 | 789 / 1809 | 89% | 16.40 | 422 / 472 |
| pancreas | 34% | 1945.70 | 112 / 328 | 97% | 25.92 | 172 / 178 |
| blood vessel | 100% | 42737.14 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 39.67 | 80 / 80 |
| ureter | 0% | 0 | 0 / 0 | 100% | 24.29 | 1 / 1 |
| adipose | 100% | 18771.51 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| heart | 94% | 9852.30 | 811 / 861 | 0% | 0 | 0 / 0 |
| spleen | 78% | 5578.54 | 187 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 44% | 4.93 | 20 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 21% | 1.62 | 6 / 29 |
| brain | 1% | 30.18 | 14 / 2642 | 20% | 2.19 | 141 / 705 |
| muscle | 6% | 344.11 | 47 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 5.12 | 1 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006396 | Biological process | RNA processing |
| GO_0000381 | Biological process | regulation of alternative mRNA splicing, via spliceosome |
| GO_0065003 | Biological process | protein-containing complex assembly |
| GO_0060395 | Biological process | SMAD protein signal transduction |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0006979 | Biological process | response to oxidative stress |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0000932 | Cellular component | P-body |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0010494 | Cellular component | cytoplasmic stress granule |
| GO_0005634 | Cellular component | nucleus |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0060090 | Molecular function | molecular adaptor activity |
| GO_0097157 | Molecular function | pre-mRNA intronic binding |
| GO_0003729 | Molecular function | mRNA binding |
| GO_1990715 | Molecular function | mRNA CDS binding |
| GO_0003723 | Molecular function | RNA binding |
| GO_0003713 | Molecular function | transcription coactivator activity |
| GO_0003730 | Molecular function | mRNA 3'-UTR binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | RBPMS |
| Protein name | HCG2043421, isoform CRA_c (RNA binding protein, mRNA processing factor) (cDNA FLJ61582, highly similar to RNA-binding protein with multiple splicing) RNA binding protein, mRNA processing factor RNA-binding protein with multiple splicing (RBP-MS) (RBPMS) (Heart and RRM expressed sequence) (Hermes) RNA binding protein with multiple splicing |
| Synonyms | HERMES hCG_2043421 |
| Description | FUNCTION: [Isoform A]: RNA binding protein that mediates the regulation of pre-mRNA alternative splicing (AS) . Acts either as activator (FLNB, HSPG2, LIPA1, MYOCD, PTPRF and PPFIBP1) or repressor (TPM1, ACTN1, ITGA7, PIEZO1, LSM14B, MBNL1 and MBML2) of splicing events on specific pre-mRNA targets (By similarity). Together with RNA binding proteins RBFOX2 and MBNL1/2, activates a splicing program associated with differentiated contractile vascular smooth muscle cells (SMC) by regulating AS of numerous pre-mRNA involved in actin cytoskeleton and focal adhesion machineries, suggesting a role in promoting a cell differentiated state (By similarity). Binds to introns, exons and 3'-UTR associated with tandem CAC trinucleotide motifs separated by a variable spacer region, at a minimum as a dimer. The minimal length of RNA required for RBPMS-binding tandem CAC motifs is 15 nt, with spacing ranging from 1 to 9 nt. Can also bind to CA dinucleotide repeats . Mediates repression of TPM1 exon 3 by binding to CAC tandem repeats in the flanking intronic regions, followed by higher-order oligomerization and heterotypic interactions with other splicing regulators including MBNL1 and RBFOX2, which prevents assembly of ATP-dependent splicing complexes (By similarity). .; FUNCTION: [Isoform C]: Acts as a regulator of pre-mRNA alternative splicing (AS) (By similarity). Binds mRNA . Regulates AS of ACTN1, FLNB, although with lower efficiency than isoform A / RBPMSA (By similarity). Acts as coactivator of SMAD transcriptional activity in a TGFB1-dependent manner, possibly through increased phosphorylation of SMAD2 and SMAD3 at the C-terminal SSXS regions and promotion of the nuclear accumulation of SMAD proteins . . |
| Accessions | E5RJ31 ENST00000397323.9 [Q93062-1] ENST00000519647.5 Q569H2 ENST00000522694.1 ENST00000287771.9 [Q93062-2] ENST00000523115.5 H0YC46 H0YBU9 Q93062 ENST00000517860.5 E5RJD7 ENST00000520191.5 ENST00000339877.8 [Q93062-3] ENST00000520161.5 E5RFP4 ENST00000519359.5 B4E3T4 ENST00000320203.8 [Q93062-1] |